Findings about use of Azithromycin as COVID-19 intervention from study of hospitalized patients in New York City
-
Hazard ratio for in-hospital mortality amongst hospitalized patients in New York City were not significantly different for those given Azithromycin
-
Odds of cardiac arrest were not higher amongst patients given Azithromycin compared to those who got Hydrochloroquine, Azithromycin+Hydrochloroquine, or neither drug.
-
Patients who received Azithromycin did not have higher odds of abnormal ECG findings compared to those who got Hydrochloroquine, Azithromycin+Hydrochloroquine, or neither drug.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Learn After
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State